consumer care products
- Business Wire
Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis
Atopic dermatitis is the most common type of eczema. Moderate to severe atopic dermatitis is a chronic and incurable condition,…
Read More » - Health
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure®/ Dysport® (abobotulinumtoxinA)
Lausanne, Switzerland: Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the…
Read More »